Bio Path Holdings Inc (BPTH)

[Paullee]

Bio-Path Receives Notice of Allowance for Strategic Patent for Prexigebersen in Combination with Front Line Cytidine Analogues or Bcr-Abl Tyrosine Kinase Inhibitors in a Variety of Cancers
Bio-Path Holdings, Inc.
Thu, October 22, 2020, 7:00 AM EDT
Growing Patent Estate Creates Value and Supports Key Combination Therapies

HOUSTON, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that the United States Patent and Trademark Office has issued a notice of allowance for claims related to the Company’s lead product candidate, prexigebersen, in combination with either a cytidine analogue, such as decitabine, or the Bcr-Abl tyrosine kinase inhibitors dasatinib and nilotinib. Prexigebersen is a liposomal formulation containing the antisense oligodeoxynucleotide targeting growth factor receptor-bound protein 2 (Grb2).

The new patent, titled, “Combination Therapy with Liposomal Antisense Oligonucleotides,” (based on Application No. 16/333,221), will provide broad protection for application of prexigebersen in the treatment of a variety of cancers in combination with front-line therapies.

“This further strengthens our intellectual property portfolio and complements already granted patents. Our growing patent estate continues to be a valuable asset for Bio-Path as it provides protection not only for our core product portfolio and research efforts but now also offers broad protection in combination with established front-line therapies,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings.

“Bio-Path is currently in an ongoing Phase 2 clinical trial of prexigebersen in combination with decitabine as a treatment for acute myeloid leukemia (AML), and this new patent protects the unique therapy combination and supports our ongoing investment in this program to bring a new treatment option to patients with AML who have limited treatment options,” added Mr. Nielsen.

[Awl416]

News

[makingitnow]

This Patent news they got today. I am looking for advice from more of a biotec kinda guy. How relevant is it? with the news Presenting that came out the 9th seems like they may have somthing going on positive. Thoughts?

[SloDan]

WTH - Haven't we heard all this before?? News Flash Peter, we are 8 1/2 months into 2020, so why all the 2019 Blabber.

[blairsoldman]

The press release references the web site. This contains the wonderfully hopeful statements that kept us happy four years ago, before the disillusionment and the 200:1 RSS. Remember when we loved reading:
++++++++++++++++++++++++
Current Development Status

- Based on successful results of a Phase 1 clinical trial, Bio-Path has initiated a Phase 2 program in AML, comprised of two clinical trials of BP1001 in combination with the first-line standard-of-care chemotherapy, low dose Ara C (LDAC):

The first has been initiated in 54 newly diagnosed AML patients who are not eligible for or who have decided to forego intensive induction therapy because of their age or fragile health.
A second study in relapsed and refractory AML patients is expected to be initiated in 2017.

- Prexigebersen has also completed a Phase 1 clinical trial in patients with CML and expects to initiate enrollment before the end of 2016 for the dose-determining segment of a Phase 2 trial of prexigebersen in combination with first-line standard-of-care for CML, dasatinib.

+++++++++++++++
WOW. THe expectations for 2016 and 2017.
WHAT HAPPENED???

WTF has been done in the four years since that "Current Status" was written?

Where have they spent all that money?

Presentations to try to get new investment are not what is needed. What is needed are presentations by credible scientists on what has been done in the last four years and what results have been obtained.

[blairsoldman]

So PN is going on the road again after ?how many years? to try to re kick start this scam. He will surely drone on in his own inimical boring manner over mostly three year old results. How many decades can he keep this up?

http://www.globenewswire.com/news-release/2020/09/09/2090818/0/en/Bio-Path-Holdings-to-Present-at-the-H-C-Wainwright-22nd-Annual-Global-Investment-Conference.html

[SJSTOCKSHARK]

BPTH better get move on with the trials. The only have enough cash to last another year.

[benchman]

Unfortunately, today was not a repeat performance

[ClayTrader]

* * $BPTH Video Chart 08-21-2020 * *

Link to Video - click here to watch the technical chart video

[kingsplay]

This sock has made me a lot of money in the past. I saw this stock go from $2 to $72 in less than 2 weeks. The day it ran to $72 it opened at $18 closed at $38. Volume was 36,000,000 shares traded. I made a really nice return on my money that week. This is a stock that you buy what you can afford and sale small partials as it gains momentum. I bought back in in the 3's hoping for another amazing run. Fundamentally there is a good chance this company could stumble upon a successful treatment for cancer. They are connected to MD Anderson hospital here in Houston.

[Paullee]

yeah, but at this volume with so little movement, it doesn't make sense

[whytestocks]

JUST IN: $BPTH Are Penny Stocks Worth It? 3 On The Rise This Week

Penny Stocks To Watch Before The Weekend Are penny stocks worth it? It’s not a rhetorical question and one I’m sure people ask themselves every time they look at small-cap stocks . I’m sure that if you’re reading this, you’ve got some interest in making ...

Got this from BPTH - Are Penny Stocks Worth It? 3 On The Rise This Week

[benchman]

A lot of buying and selling in the same day. See this article below:

https://www.investopedia.com/ask/answers/05/sharestradedoutstanding.asp

[Paullee]

How can they do 4.2 mil shs at noon, when there is only 3.7 mil shs o/s

[benchman]

I'll take $72 $BPTH

[kingsplay]

I wonder if this is going to repeat last years run? Ity started off the same way. Large purchases, then huge short volume followed by huge buys again forceing a short squeeze that ran the price to $72. I could sure use the money.

[whytestocks]

News: $BPTH Bio-Path Holdings Announces First Patient Dosed in Amended Stage 2 of the Phase 2 Clinical Trial Evaluating Prexigebersen in Acute Myeloid Leukemia

HOUSTON, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the enrollment and dos...

Got this from BPTH - Bio-Path Holdings Announces First Patient Dosed in Amended Stage 2 of the Phase 2 Clinical Trial Evaluating Prexigebersen in Acute Myeloid Leukemia

[SJSTOCKSHARK]

I sold my last shares of BPTH for a tax loss sometime ago. The stock that got me into this field was Tekmira now ABUS. They got good news on their patent fight with MRNA. I have held every share of ABUS and even added recently. It may be worth following. They have some great scientific talent.

Read up before buying. This is not a recommendation to buy.

Good luck all!

[Doc74]

Thanks for the update and history lesson.

[blairsoldman]

The link says the study started in May 2016. WOW. Those were the days!!! I remember we on this message board thought we would have results by the end of 2017 and we would not only be rich but would have helped humanity overcome another scourge.

The stock hit $638 (pre 200:1 RSS adjusted). Happy days.

It would be kinda interesting to know what progress there is. How many of the 108 (if any) have actually been in treatment and if any have shown remission. I recall that it started with needing 21 (or thereabouts), how the heck did it get to 108?

The web site says:
BP1002 (Liposomal Bcl2 Antisense)

Bio-Path is planning to initiate a Phase 1 clinical trial of BP1002 in patients with follicular lymphoma, the most common form of non-Hodgkin’s lymphoma (NHL) in 2017.

Still planning for 2017 I see - have they missed the boat?

I stick with my belief that this was a hoax from the start and any remaining stock holders (such as me) are just being strung along in the hope we don't wise up and sue. Has anyone been to the office address to see if it looks like a real operation, not just a conman and secretary living it up.

[Doc74]

Thanks for the link, we may be waiting for some time.
Estimated Study Completion Date :December 2021

[Mt Bobster]

No new news for a long time. Anyone else out there. I found this on yahoo blog. https://clinicaltrials.gov/ct2/show/NCT02781883
from 12 days ago.

[slapshot120]

pretty obvious from the activity on this board that people have no faith in peter .. what a screwing he gave all the original investors with his reverse stock splits.In my investment experience I have never seen 2 reverses in a 6 month period.

[Pat Torney]

I used to post here all the time, mostly trying to sound the warning cry that Peter has no idea what he is doing. I come check the board now about once every couple of months, but I don't really post much any more because Peter got exactly what he wanted from all of the reverse splits, I have next to nothing left.

[Doc74]

Your think that does not happen more often than anyone knows. I am in for the long run. It is about time that this stock has a good run to get people back interested. Only a few post here monthly. I would say investors have lost all interest in Bio-Path.

[SJSTOCKSHARK]

Would that not be insider trading?

[Runninonempty]

That is likely true AND the fact that PN just gave himself cheap warrants. He knew the bottom was in and something big is coming IMHO

[SJSTOCKSHARK]

Why the jump in PPS today? It must be because I sold all my shares.

[SJSTOCKSHARK]

No nibbling here! I have sold ALL my shares. I will not look at this company until a PPS of $2 or less. It looks PN and the boys priced their compensation shares too high. OOOPPPPSS!

I suspect they will be re-priced soon.

[slapshot120]

I smell a reverse stock split coming

[slapshot120]

no worries pete doesn't play golf.if he did he couldn't hit the broad side of a barn door

[too simple]

Not me ! I am nibbling at others - so many other potential good buys out there .
I paid for enough of PN’s golf rounds .

[Billlowenswartz]

I have such a toxic relationship with this stock. It doesn't ever give me anything in return but I keep coming back to it. Is there reason to believe that something will change? Does the move to a new all be it expensive accounting firm change any thing in your opinions? Are any of you buying at this price?

[Billlowenswartz]

I have such a toxic relationship with this stock. It doesn't ever give me anything in return but I keep coming back to it. Does the move to a new all be it expensive accounting firm change any thing in your opinions? Are any of you buying at this low price?

[SJSTOCKSHARK]

Runin, I seems to me PN is most excited about BP1003 the stat3 drug.

https://www.bostonbiomedical.com/science/targeting-cancer-cell-subsets/stat3-pathway/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2610472/

He may be right but as usual where is the urgency? PN was urgent about putting 600,000 shares aside as potential compensation for him and the employees.

There has been work on stat3 drugs for years. No human trials yet for BPTH with less than 3 years of money left. Almost a year since they knew the results on last years poster. Too busy loading up their pockets?

[Runninonempty]

I have been listening to PN’s conference calls for years and I have never heard him this excited before. Things will be changing soon with this fledgling company IMHO

[SJSTOCKSHARK]

Results are out. Only $20 million left. Two years left to get something done.

Burn rate up to $8.6 million. Got to pay to keep good people. Thx PN.

Same old song and dance. Look out below.

When if ever is this stock a buy?

[nsomniyak]

The chart looks a whole lot different a year after a big move.

[Runninonempty]

Dead cat bounce, anniversary of huge move, test results coming, joint venture coming, PN retiring (we could only hope), etc. take your pick

[Doc74]

So why the big move today, not seeing anything that supports the 15+% jump.

[blairsoldman]

[SJSTOCKSHARK]

Another buck to downside and I may start wading in again.

[SJSTOCKSHARK]

More sellers of BPTH.

http://archive.fast-edgar.com/20200214/A22ZO22CZW2R39ZZ2H2F2ZYSNWAFZZ22ZI22

[SJSTOCKSHARK]

No, I meant from the BOD position. Perhaps they will now release news. Shorting could still happen from other entities.

[Billlowenswartz]

SJ
I saw your post on Stocktwits and below. Excuse my ignorance but when you say that now there is no more reason for them to push the price down. Does that change your buy point of below $5.00?

[SJSTOCKSHARK]

Up to $4 million for PN and more dilution for the
shareholders


CALCULATION OF REGISTRATION FEE


Common Stock, $0.001 par value per share 600,000
shares (2) $ 6.33 $ 3,798,000 $ 492.98



(1) Pursuant to Rule 416 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement is deemed to include additional shares of common stock issuable under the terms of the Bio-Path Holdings, Inc. 2017 Stock Incentive Plan, as amended by the First Amendment to Bio-Path Holdings, Inc. 2017 Stock Incentive Plan (as so amended, the “Plan”), by reason of any stock dividend, stock split, recapitalization or other similar transaction.
(2) Consists of shares of common stock issuable in respect of awards to be granted under the Plan.
(3) Estimated solely for the purpose of calculating the registration fee in accordance with Rules 457(c) and (h) promulgated under the Securities Act, based upon the average of the high and low prices of Bio-Path Holdings, Inc.’s common stock as reported on The Nasdaq Capital Market on February 11, 2020.


REGISTRATION OF ADDITIONAL SECURITIES PURSUANT TO GENERAL INSTRUCTION E


Bio-Path Holdings, Inc. (the “Company”) has filed this Registration Statement to register under the Securities Act of 1933, as amended, the offer and sale of an additional 600,000 shares of common stock of the Company, par value $0.001 per share, issuable under the Bio-Path Holdings, Inc. 2017 Stock Incentive Plan, as amended by the First Amendment to Bio-Path Holdings, Inc. 2017 Stock Incentive Plan (as so amended, the “Plan”). Accordingly, the contents of the previous Registration Statement on Form S-8 (File No. 333-223111) filed by the Company with the U.S. Securities and Exchange Commission on February 20, 2018 (the “Prior Registration Statement”) relating to the Plan, including periodic reports that the Company filed after the Prior Registration Statement to maintain current information about the Company, are incorporated by reference into this Registration Statement pursuant to General Instruction E of Form S-8. The Prior Registration Statement is currently effective.

[too simple]

SJ, your a smart man. I also sold most of mine in the 20’s ( which was not that much after he chewed it to the bone ). But, I nibbled a few in the teens which today was a mistake. I think I am going to just wait. Had very good luck with a few others which has set me up now . I check in once in a while and may take a run at some if it looks like something may happen. As always wish everyone here good luck !

[SJSTOCKSHARK]

They need to keep at least a million shares. Unless the do more financing deals another R?S in unlikely for the next 2 years.

I still believe the science has value if the patents hold up.

Presently the market cap is close to cash on hand.

[blairsoldman]

You still believe!!
I would not be surprised if this went down below 5cents again and PN did a 20:1 RSS. Keep milking until the cow croaks.

[SJSTOCKSHARK]

Oldman, This may be a buy if we drop below $5. I may start adding some until we hit $2 bucks and then load up. I sold the majority of my shares between $21-$25.